Literature DB >> 25830136

Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective.

Meet Kumar1, Prakas Mandal1, Rajib De1, Pinaki Mukherjee2, Tuphan Kanti Dolai1, Maitryee Bhattyacharyya1.   

Abstract

Entities:  

Year:  2015        PMID： 25830136      PMCID： PMC4377346          DOI： 10.5045/br.2015.50.1.63

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  11 in total

1.  Management of hemolytic uremic syndrome.

Authors:  Chantal Loirat; Jeffrey Saland; Martin Bitzan
Journal:  Presse Med       Date:  2012-01-27       Impact factor: 1.228

2.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

3.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

4.  Eculizumab for congenital atypical hemolytic-uremic syndrome.

Authors:  Ralph A Gruppo; Russell P Rother
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

5.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

6.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Chantal Loirat; Sylvie Cloarec; Marie-Alice Macher; Jacques Blouin; Hubert Nivet; Laurence Weiss; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

7.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gerard Socié; Petra Muus; Alexander Röth; Jeffrey Szer; Modupe O Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

8.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

9.  Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

Authors:  C Mark Taylor; Sam Machin; Stephen J Wigmore; Tim H J Goodship
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

Review 10.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.